Janssen sees USD 12bn sales potential in Genmab-developed drugs

Three potential candidates from Genmab have a USD 4bn top sales potential each, says Head of the Global Oncology Therapeutic Area at Janssen Peter Lebowitz.


Genmab is already bringing in most of its top line revenue from partner Johnson & Johnson's sales of Darzalex, which is a Genmab-developed drug, but revenue streams from Johnson & Johnson's pharmaceutical arm could be considerably increased in the future, reports Danish business daily Børsen.

In a presentation, Peter Lebowitz, head of the Global Oncology Therapeutic Area at Janssen, says that six more portfolio candidates could see approvals or submissions for approvals before the end of 2023 – three of which are potential candidates developed by Genmab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs